Amryt Pharma plc [AMYT] vs Johnson & Johnson [JNJ] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Amryt Pharma plc wins in 3 metrics, Johnson & Johnson wins in 10 metrics, with 2 ties. Johnson & Johnson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amryt Pharma plc | Johnson & Johnson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 39.73 | 20.49 | Johnson & Johnson |
| Price-to-Book Ratio | 2.80 | 6.68 | Amryt Pharma plc |
| Debt-to-Equity Ratio | 164.32 | 60.50 | Johnson & Johnson |
| PEG Ratio | -0.39 | 0.42 | Johnson & Johnson |
| EV/EBITDA | 0.00 | 16.84 | Tie |
| Profit Margin (TTM) | 52.32% | 21.83% | Amryt Pharma plc |
| Operating Margin (TTM) | -0.86% | 26.72% | Johnson & Johnson |
| EBITDA Margin (TTM) | N/A | 26.72% | N/A |
| Return on Equity | -94.18% | 32.87% | Johnson & Johnson |
| Return on Assets (TTM) | -2.32% | 13.46% | Johnson & Johnson |
| Free Cash Flow (TTM) | N/A | $19.31B | N/A |
| Dividend Yield | N/A | 2.09% | N/A |
| 1-Year Return | N/A | 53.32% | N/A |
| Price-to-Sales Ratio (TTM) | 4.24 | 5.66 | Amryt Pharma plc |
| Enterprise Value | $0 | $574.25B | Johnson & Johnson |
| EV/Revenue Ratio | 0.00 | 5.96 | Tie |
| Gross Profit Margin (TTM) | 44.86% | 67.56% | Johnson & Johnson |
| Revenue per Share (TTM) | $5 | $40 | Johnson & Johnson |
| Earnings per Share (Diluted) | $0.02 | $11.04 | Johnson & Johnson |
| Beta (Stock Volatility) | N/A | 0.33 | N/A |
| Short % of Float | N/A | 1.03% | N/A |
Amryt Pharma plc vs Johnson & Johnson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amryt Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Johnson & Johnson | -2.16% | 1.51% | 3.95% | -3.10% | 10.03% | 13.65% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amryt Pharma plc | N/A | N/A | N/A | N/A | N/A | N/A |
| Johnson & Johnson | 53.32% | 46.67% | 48.70% | 108.58% | 263.36% | 290.52% |
Performance & Financial Health Analysis: Amryt Pharma plc vs Johnson & Johnson
| Metric | AMYT | JNJ |
|---|---|---|
| Market Information | ||
| Market Cap | N/A | $555.84B |
| Market Cap Category | N/A | Mega cap |
| 10 Day Avg. Volume | 2,376,385 | 8,370,566 |
| 90 Day Avg. Volume | 1,458,182 | 7,752,965 |
| Last Close | $14.70 | $235.66 |
| 52 Week Range | $14.70 - $14.71 | $149.04 - $251.71 |
| % from 52W High | -0.07% | -6.38% |
| All-Time High | $14.71 (Jan 16, 2025) | $251.71 (Mar 02, 2026) |
| % from All-Time High | -0.07% | -6.38% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.11% | 0.10% |
| Quarterly Earnings Growth | N/A | -0.52% |
| Financial Health | ||
| Profit Margin (TTM) | 0.52% | 0.22% |
| Operating Margin (TTM) | -0.01% | 0.27% |
| Return on Equity (TTM) | -0.94% | 0.33% |
| Debt to Equity (MRQ) | 164.32 | 60.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.02 | $33.87 |
| Cash per Share (MRQ) | $1.30 | $8.34 |
| Operating Cash Flow (TTM) | $-29,023,000 | $22.21B |
| Levered Free Cash Flow (TTM) | $-18,171,000 | $43.47B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.09% |
| Last 12-Month Dividend | N/A | $5.20 |
Valuation & Enterprise Metrics Analysis: Amryt Pharma plc vs Johnson & Johnson
| Metric | AMYT (Mar 31, 2025) | JNJ (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 39.73 | 20.49 |
| Forward P/E | -490.00 | 17.80 |
| PEG Ratio | -0.39 | 0.42 |
| Price to Sales (TTM) | 4.24 | 5.66 |
| Price to Book (MRQ) | 2.80 | 6.68 |
| Market Capitalization | ||
| Market Capitalization | $942.77M | $555.84B |
| Enterprise Value | $0 | $574.25B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.00 | 5.96 |
| Enterprise to EBITDA | 0.00 | 16.84 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.33 |
| Book Value per Share (MRQ) | $0.02 | $33.87 |
Financial Statements Comparison: Amryt Pharma plc vs Johnson & Johnson
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | AMYT | JNJ (2025) |
|---|---|---|
| Revenue/Sales | N/A | 94.19B |
| Cost of Goods Sold | N/A | 30.26B |
| COGS % of Revenue | - | 32.1% |
| Gross Profit | N/A | 63.94B |
| Gross Margin | - | 67.9% |
| Research & Development | N/A | 14.67B |
| Operating Income (EBIT) | N/A | 25.60B |
| Operating Margin | - | 27.2% |
| EBITDA | N/A | 35.16B |
| EBITDA Margin | - | 37.3% |
| Pre-Tax Income | N/A | 32.58B |
| Pre-Tax Income % of Revenue | - | 34.6% |
| Income Tax | N/A | 5.78B |
| Income Tax % of Revenue | - | 6.1% |
| Net Income (Profit) | N/A | 26.80B |
| Profit Margin | - | 28.5% |
Balance Sheet & Liquidity Metrics
| Metric | AMYT | JNJ (2025) |
|---|---|---|
| Cash & Equivalents | N/A | 19.71B |
| Total Current Assets | N/A | 55.62B |
| Total Current Assets % of Revenue | - | 59.1% |
| Total Current Liabilities | N/A | 54.13B |
| Total Current Liabilities % of Revenue | - | 57.5% |
| Long-Term Debt | N/A | 39.44B |
| Long-Term Debt % of Revenue | - | 41.9% |
| Total Shareholders Equity | N/A | 81.54B |
| Retained Earnings | N/A | N/A |
| Retained Earnings % of Revenue | - | 0.0% |
| Property, Plant & Equipment | N/A | 0 |
Cash Flow Statement Comparison
| Metric | AMYT | JNJ (2025) |
|---|---|---|
| Operating Cash Flow | N/A | 22.21B |
| Operating Cash Flow % of Revenue | - | 23.6% |
| Capital Expenditures | N/A | -4.83B |
| Free Cash Flow | N/A | 19.31B |
| FCF Margin | - | 20.5% |
| Debt Repayment | N/A | -14.09B |
| Common Stock Repurchase | N/A | -5.95B |
Short Interest & Institutional Ownership Analysis
| Metric | AMYT | JNJ |
|---|---|---|
| Shares Short | N/A | 22.27M |
| Short Ratio | N/A | 2.90 |
| Short % of Float | N/A | 1.03% |
| Shares Outstanding | 64.13M | 2.41B |
| Float Shares | N/A | 2.41B |
| % Held by Insiders | N/A | 0.06% |
| % Held by Institutions | N/A | 75.84% |
| % Held by Public | N/A | 24.10% |
Dividend Analysis & Yield Comparison: Amryt Pharma plc vs Johnson & Johnson
| Metric | AMYT | JNJ |
|---|---|---|
| Last 12-Month Dividend | N/A | $5.20 |
| Last 12-Month Dividend Yield | N/A | 2.09% |
| 3-Year Avg Annual Dividend | N/A | $4.97 |
| 3-Year Avg Dividend Yield | N/A | 0.74% |
| 3-Year Total Dividends | N/A | $14.92 |
| Ex-Dividend Date | N/A | Feb 24, 2026 |